{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:13:14Z","timestamp":1780582394523,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"PharmoRx Therapeutics"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jad.2016.08.029","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T04:59:07Z","timestamp":1475816347000},"page":"6-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants"],"prefix":"10.1016","volume":"208","author":[{"given":"David","family":"Mischoulon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Hylek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert S.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisabet J.","family":"Clain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cusin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn Flosnik","family":"Ionescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Alpert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Soskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2016.08.029_bib1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/0269881115586937","article-title":"Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice","volume":"29","author":"Almatroudi","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2016.08.029_bib2","series-title":"Handbook of Chronic Depression: Diagnosis and Therapeutic Management","first-page":"25","author":"Alpert","year":"2004"},{"key":"10.1016\/j.jad.2016.08.029_bib3","unstructured":"Bear, D.M., Kessler, R.M., 2014a. United States Patent 8,883,831."},{"key":"10.1016\/j.jad.2016.08.029_bib4","unstructured":"Bear, D.M., Kessler, R.M., 2014b. US Patent Application PCT\/US2014\/013874. Washington, DC: U.S."},{"key":"10.1016\/j.jad.2016.08.029_bib5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archgenpsychiatry.2011.2094","article-title":"Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration","volume":"69","author":"Capuron","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2016.08.029_bib6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1755-5949.2009.00102.x","article-title":"RESEARCH: validation of the massachusetts general hospital antidepressant treatment history questionnaire (ATRQ)","volume":"16","author":"Chandler","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jad.2016.08.029_bib7","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.jad.2016.08.029_bib8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0361-9230(98)00054-9","article-title":"Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area","volume":"46","author":"Di Mascio","year":"1998","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.jad.2016.08.029_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archpsyc.64.3.327","article-title":"The role of dopamine in the pathophysiology of depression","volume":"64","author":"Dunlop","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2016.08.029_bib10","first-page":"321","article-title":"Quality of life enjoyment and satisfaction questionnaire: a new measure","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2016.08.029_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000201934","article-title":"Reliability and validity of the Massachusetts General Hospital cognitive and physical functioning questionnaire","volume":"78","author":"Fava","year":"2009","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2016.08.029_bib12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000012299","article-title":"An open trial of oral sildenafilin antidepressant-induced sexual dysfunction","volume":"67","author":"Fava","year":"1998","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2016.08.029_bib13","first-page":"18","article-title":"Levodopa reverses cytokine-induced reductions in striatal dopamine release","author":"Felger","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2016.08.029_bib14","series-title":"Biometrics Research Department","article-title":"Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID I\/P)","author":"First","year":"1995"},{"key":"10.1016\/j.jad.2016.08.029_bib15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0140-6736(03)12599-8","article-title":"Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review","volume":"361","author":"Geddes","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2016.08.029_bib16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.bbi.2003.12.001","article-title":"The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-alpha production","volume":"18","author":"Greeneltch","year":"2004","journal-title":"Brain, Behav., Immun."},{"key":"10.1016\/j.jad.2016.08.029_bib17","series-title":"ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM)76-338","year":"1976"},{"key":"10.1016\/j.jad.2016.08.029_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol., Neurosurg., Psychiatry"},{"key":"10.1016\/j.jad.2016.08.029_bib19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00213-008-1088-9","article-title":"Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET","volume":"197","author":"Hirvonen","year":"2008","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.jad.2016.08.029_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1460-9568.2008.06321.x","article-title":"Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)","volume":"28","author":"Hutchinson","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.jad.2016.08.029_bib21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0006-3223(02)01383-5","article-title":"Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study","volume":"52","author":"Klimek","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2016.08.029_bib22","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/archpsyc.57.8.787","article-title":"Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders","volume":"57","author":"Lambert","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2016.08.029_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00788510","article-title":"Assessing impairment in patients with panic disorder: the Sheehan Disability Scale","volume":"27","author":"Leon","year":"1992","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.jad.2016.08.029_bib24","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00004714-199212000-00017","article-title":"General versus specific inquiry with SAFTEE","volume":"12","author":"Levine","year":"1992","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2016.08.029_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","article-title":"Opioid receptors: distinct roles in mood disorders","volume":"36","author":"Lutz","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jad.2016.08.029_bib26","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1176\/ajp.2006.163.9.1594","article-title":"Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study","volume":"163","author":"Meyer","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.08.029_bib27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4088\/JCP.13m08591","article-title":"A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-l-methionine (SAMe) vs. escitalopram in major depressive disorder","volume":"75","author":"Mischoulon","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.08.029_bib28","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression rating scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.08.029_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1192\/S0007125000297328","article-title":"The prophylactic efficacy of fluoxetine in unipolar depression","volume":"3","author":"Montgomery","year":"1988","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.jad.2016.08.029_bib30","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1176\/ajp.156.7.1000","article-title":"Recurrence after recovery from major depressive disorder during 15 years of observational follow-up","volume":"156","author":"Mueller","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.08.029_bib31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0006-3223(01)01089-7","article-title":"Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression","volume":"50","author":"Parsey","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2016.08.029_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0278-5846(91)90042-Y","article-title":"The prophylactic efficacy of tricyclic antidepressants--a five year followup","volume":"15","author":"Peselow","year":"1991","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2016.08.029_bib33","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1017\/S0033291700033134","article-title":"Remission and relapse in major depression: a two-year prospective follow-up study","volume":"25","author":"Ramana","year":"1995","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2016.08.029_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.eplepsyres.2008.10.011","article-title":"Tolerance to the anticonvulsant effect of morphine in mice: blockage by ultra-low dose naltrexone","volume":"83","author":"Roshanpour","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jad.2016.08.029_bib35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archpsyc.1986.01800040066010","article-title":"Cerebrospinal fluid monoamine and monoamine metabolite levels and the dexamethasone suppression test in depression. Relationship to life events","volume":"43","author":"Roy","year":"1986","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2016.08.029_bib36","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/sj.npp.1301131","article-title":"Report by the ACNP Task Force on response and remission in major depressive disorder","volume":"31","author":"Rush","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2016.08.029_bib37","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.08.029_bib38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/bmj.327.7407.158","article-title":"Separation of anxiety and depressive disorders: blind alley in psychopharmacology and classification of disease","volume":"327","author":"Shorter","year":"2003","journal-title":"BMJ (Clin. Res. Ed. )"},{"key":"10.1016\/j.jad.2016.08.029_bib39","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","article-title":"Low-dose naltrexone therapy improves active crohn\u2019s disease","volume":"102","author":"Smith","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jad.2016.08.029_bib40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/S1092852913000345","article-title":"Incentive salience: novel treatment strategies for major depression","volume":"18","author":"Soskin","year":"2013","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2016.08.029_bib41","series-title":"Stahl\u2019s Essential Psychopharmacology: The Prescriber\u2019s Guide. Antidepressants","author":"Stahl","year":"2011"},{"key":"10.1016\/j.jad.2016.08.029_bib42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S0033291703001107","volume":"34","author":"Trivedi","year":"2004","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2016.08.029_bib43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/07357909509024923","article-title":"Treatment of neurotoxic side effects of interferon-alpha with naltrexone","volume":"13","author":"Valentine","year":"1995","journal-title":"Cancer Investig."},{"key":"10.1016\/j.jad.2016.08.029_bib44","doi-asserted-by":"crossref","first-page":"e1554","DOI":"10.1371\/journal.pone.0001554","article-title":"High-affinity naloxone binding to filamin a prevents mu opioid receptor-gs coupling underlying opioid tolerance and dependence","volume":"3","author":"Wang","year":"2008","journal-title":"PloS One"},{"key":"10.1016\/j.jad.2016.08.029_bib45","series-title":"Handbook of Physiology: Dopamine in the CNS","first-page":"387","article-title":"Dopamine and depression","author":"Willner","year":"2002"},{"key":"10.1016\/j.jad.2016.08.029_bib46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jad.2004.12.010","article-title":"Dopaminergic mechanism of antidepressant action in depressed patients","volume":"86","author":"Willner","year":"2005","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2016.08.029_bib47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study","volume":"10","author":"Younger","year":"2009","journal-title":"Pain. Med. (Malden, Mass. )"}],"updated-by":[{"DOI":"10.1016\/j.jad.2017.10.040","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000}}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032716304499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032716304499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T10:42:56Z","timestamp":1692528176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032716304499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":47,"alternative-id":["S0165032716304499"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2016.08.029","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jad.2017.10.040","asserted-by":"object"}]},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2016.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}